FORMULATION DEVELOPMENT AND EVALUATION OF SUSTAINED RELEASE TABLET CHLORPROMAZINE HCL

Mr. Bhavar Ganesh Dattu* and Prof. S. S. Gaikwad

Chlorpromazine HCl was selected as a candidate for the development of sustained- release tablets. Drugs are often given to patients through the oral route. Patients and doctors alike tend to choose tablets as the best oral formulation currently on the market. Using an extended release dosage form may increase a drug's therapeutic efficacy by maintaining a plasma concentration of the drug that is two- to three-fold higher than when the drug is taken directly. The use of polymers into dosage forms is currently standard practice with the aim of improving drug delivery. The microcrystalline cellulose (MCC) was used as the direct compressible agent, while the magnesium stearate was used not only as a crosslinking agent but also as a lubricant and slip agent. Polyvinylpyrrolidone (PVP) served as a binding agent. The medicine and excipients did not interact negatively, according to the FT-IR study of the two substances. After extensive prestressing research into factors like angle of repose, bulk density, thread density, Carr index, and Haunser ratio, the powder combinations demonstrated compression and good to fair compression. Compression's effects on formulations' weight, hardness, thickness, friability, medicine content, and in vitro dissolution were tested extensively. Preparation results in tablets with a hardness and thickness of 6.0–8.0 kg/cm2. Not only did everything fall inside the accepted range of 3.5–4.0mm, but it also satisfied all other normative requirements. The in vitro dissolution investigation revealed that after 24 hours, the drug release from formulations F4 and F7 was 99.54 and 98.78 percent effective, respectively.